Cargando…

Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel

Berberine is the major constituent of Coptis chinese and is commonly used in Chinese herbal medicine to treat patients with gastrointestinal disorders. In this study, using flow cytometry, we have found that a 24-h berberine treatment up-regulated the multidrug-resistant transporter (pgp-170) expres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, H-L, Liu, T-Y, Wu, C-W, Chi, C-W
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362909/ https://www.ncbi.nlm.nih.gov/pubmed/10507765 http://dx.doi.org/10.1038/sj.bjc.6690710

Ejemplares similares

Berberine Alleviates Paclitaxel-Induced Neuropathy
por: Rezaee, Ramin, et al.
Publicado: (2019)

Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure
por: Melguizo, Consolación, et al.
Publicado: (2012)

Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium
por: Li, M, et al.
Publicado: (1999)

Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion
por: Batrakova, E V, et al.
Publicado: (2001)

Modulation of paclitaxel resistance by annexin IV in human cancer cell lines
por: Han, E Kyu-Ho, et al.
Publicado: (2000)

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line
por: Hu, X F, et al.
Publicado: (1999)

MDR1 causes resistance to the antitumour drug miltefosine
por: Rybczynska, M, et al.
Publicado: (2001)

Cross-talk between signalling pathways and the multidrug resistant protein MDR-1
por: Ding, S, et al.
Publicado: (2001)

Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
por: Earle, C C, et al.
Publicado: (1999)

Ecdysteroids Sensitize MDR and Non-MDR Cancer Cell Lines to Doxorubicin, Paclitaxel, and Vincristine but Tend to Protect Them from Cisplatin
por: Martins, Ana, et al.
Publicado: (2015)

MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells
por: Chen, G K, et al.
Publicado: (2000)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Effect of c-Abl tyrosine kinase on the cellular response to paclitaxel-induced microtubule damage
por: Nehmé, A, et al.
Publicado: (2000)

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
por: Tellingen, O van, et al.
Publicado: (1999)

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
por: Somlo, G, et al.
Publicado: (2001)

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
por: Vanhoefer, U, et al.
Publicado: (1999)

VE-Albumin Core-Shell Nanoparticles for Paclitaxel Delivery to Treat MDR Breast Cancer
por: Tang, Bo, et al.
Publicado: (2018)

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
por: Asperen, J van, et al.
Publicado: (1999)

Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918
por: Wallstab, A, et al.
Publicado: (1999)

Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells
por: Côme, M-G, et al.
Publicado: (1999)

Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer
por: Gaast, A van der, et al.
Publicado: (1999)

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

MDR1 gene expression in primary colorectal carcinomas.
por: Pirker, R., et al.
Publicado: (1993)

A phase II trial of paclitaxel and epirubicin in advanced breast cancer
por: Rischin, D, et al.
Publicado: (2000)

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer
por: Lalisang, R I, et al.
Publicado: (2000)

Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma
por: Kariyama, K, et al.
Publicado: (1999)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
por: Jagdev, S P, et al.
Publicado: (2001)

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
por: Kroep, J R, et al.
Publicado: (2000)

A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
por: Kollmannsberger, C, et al.
Publicado: (2000)

Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-α
por: Hung, W-C, et al.
Publicado: (1999)

Application of an original RT-PCR–ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients
por: Ferrero, J M, et al.
Publicado: (2000)

Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells
por: Liu, X M, et al.
Publicado: (2001)

Aurora B expression modulates paclitaxel response in non-small cell lung cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)

Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study
por: Gridelli, C, et al.
Publicado: (2001)

Preparation and Characterization of a Murine Monoclonal Antibody (MDR3M) Reactive with mdr3 Gene Product
por: Sugawara, Isamu, et al.
Publicado: (1992)

Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel
por: Hughes, A N, et al.
Publicado: (2000)

Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.
por: Stein, U., et al.
Publicado: (1996)

Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology
por: Yang, Sujeong, et al.
Publicado: (2015)

The mitohormetic response as part of the cytoprotection mechanism of berberine: Berberine induces mitohormesis and mechanisms
por: Zhu, Xiaofei, et al.
Publicado: (2020)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_948p6r4ikj2sl33kpr2l6b91bd